Double Wood's flagship Tongkat Ali isn't the trial-validated extract (that's their LJ100 bottle) and it isn't the maximum-potency UHP (that's Toniiq). It's the bottle that asks the cheapest version of a useful question: does your body respond to Tongkat at all? At $28/month for 60 days of QC'd 200:1 extract from a manufacturer that publishes batch COAs, this is the single most-honest cycle-zero buy on the Tongkat shelf — and the bottle we recommend to first-time Tongkat readers before they ever look at the patented tiers. Eight weeks reviewing the label, the COA, the supply chain, and how it actually compares to the more-expensive neighbours.
Check on AmazonAffiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Tongkat Ali guide →200:1 root extract with no specified eurycomanone percentage. Generic extract — meaningful concentration of starting material but no published standardisation marker. Batch-to-batch variance is higher than for patented LJ100 / Physta. The 1000 mg/cap dose roughly maps to ~200 mg of standardised-extract equivalent activity, in line with trial-window doses.
Double Wood publishes batch COAs on request through support — heavy metals (lead, mercury, cadmium, arsenic) and active-compound assay. cGMP-certified manufacturing. The COA is real and product-batch-specific, not a stock template. Best label transparency on the generic-extract tier of the Tongkat market.
$28/month for the trial-window equivalent dose — cheapest QC'd Tongkat on Amazon. The 60-cap bottle at 1 cap/day = 60-day supply. Per-active-mg cost only loses to bulk powder, which has zero QC. Among bottled-and-COA'd Tongkat, this is the value leader.
Single-ingredient formula — no Tribulus, no Maca, no BioPerine. Clean, single-cap morning protocol. Stacks cleanly with KSM-66 ashwagandha. Doesn't carry the marketing-junk inactive ingredients that pad bottles in the same price tier.
Community reports across the SAC member base are solid — most responders feel the libido shift at week 3-4, energy at 4-6, but the effect magnitude lags Toniiq UHP and LJ100 visibly. Roughly 60-70% of new users self-report a meaningful shift in 8 weeks vs. ~75% on patented extracts. The variance reflects the generic 200:1 vs patented standardisation gap.
“1000 mg Tongkat Ali extract per capsule — high potency.”
Numerically accurate — there are 1000 mg of 200:1 extract per cap. But '1000 mg' on a generic extract is not directly comparable to 200 mg of LJ100 or 800 mg of Toniiq UHP. Higher mg of less-concentrated material can equal less active eurycomanone than smaller doses of standardised extract. The phrasing implies higher potency than the per-active-mg math supports.
“200:1 standardised extract.”
The 200:1 ratio is real but is NOT standardisation in the supplement-industry sense. Standardisation means guaranteed minimum active-compound percentage (e.g., '≥2% eurycomanone'). A 200:1 ratio is a starting-material ratio — it tells you how much root was concentrated, not how much active compound is present. Calling it 'standardised' overstates the chemistry.
“Supports natural testosterone production and male health.”
Directionally true — Tongkat as a category supports testosterone in stressed populations (Talbott 2013 et al.) — but those trials all used patented extracts, not generic 200:1. The 'natural testosterone production' framing implies validated effects that the specific generic extract has not been directly trialled for. Real benefit, modest magnitude, evidence indirectly inherited from patented-extract studies.
“Third-party tested for purity and quality.”
Double Wood publishes batch COAs on request, covering heavy metals + active-compound assay. cGMP certified manufacturing facility. Independently verifiable — multiple buyers have confirmed receiving accurate batch-specific COAs.
“Vegan-friendly, non-GMO, gluten-free.”
Vegetable cellulose capsule, rice flour filler — vegan ingredients across the board. Non-GMO certification is real for the rice flour. Gluten-free per Double Wood's documentation; no wheat-derived inactives.
Read enough Tongkat marketing and you'll see '200:1 standardised extract' repeated until it sounds like a potency claim. It is not. The 200:1 ratio means 200 g of starting root was concentrated to 1 g of extract — a yield ratio, not an active-compound guarantee. A 200:1 extract from premium standardised root might contain 2% eurycomanone; a 200:1 from low-quality root might contain 0.2%. Patented extracts (LJ100, Physta) solve this by also guaranteeing a percentage of the active compound. Generic 200:1 does not. The bottle still works — it's still real Tongkat root concentrate — but the math is not equivalent to patented bottles at the same numeric dose.
Most generic 200:1 Tongkat on Amazon comes from supply chains with zero published QC. Double Wood is the rare exception in that price tier — batch COAs published on request, cGMP-certified manufacturing, heavy-metal testing on every batch. The $28/month is roughly $5-8 more than the cheapest no-name 200:1 bottles, but the trade-off is real verification vs. hope. For the cycle-zero buyer, that's a worthwhile premium.
Unlike the LJ100 bottle (where the trial dose is 2 caps/day), this bottle's 60-day supply at 1 cap/day = a clean 2-month cycle. The marketing matches the protocol — 1 cap/morning is the dose Double Wood's QC tested at and the dose that aligns roughly to trial-window standardised-extract equivalent activity. Don't run 2 caps/day on this bottle; the standardisation isn't there to support it, and you'll burn through the supply twice as fast for no validated benefit.
Self-reported response data from the SAC community shows ~60-70% of cycle-one users feel a meaningful shift on this bottle vs. ~75% on patented LJ100 / Physta / UHP. The gap is consistent with what published pharmacology predicts: batch-to-batch variance in generic extracts means SOME bottles deliver patented-equivalent eurycomanone and some don't. You don't know which you're getting until you take it. Patented extracts smooth this out by guaranteeing the active percentage. For most cycle-zero buyers, the 10% response-rate gap is acceptable given the price advantage.
Run this for 8 weeks. If you respond — libido shift by week 4, energy by week 6, bloodwork moves at week 8-12 — upgrade to LJ100 (Double Wood #2) for cycle two. The patented extract will deliver more consistent batch-to-batch potency at the trial dose. If you want maximum active eurycomanone per cap, go Toniiq UHP. If you didn't respond to this bottle, run one more cycle on LJ100 before declaring non-response — sometimes the standardisation matters. After two cycles of unambiguous non-response, Tongkat probably isn't your lever; check zinc, vitamin D, sleep, and testosterone bloodwork instead.
Double Wood Tongkat Ali Extract 1000 mg is the most-honest entry point on the Tongkat shelf — not because it's the best extract (it isn't), but because it's the cheapest QC'd way to answer the question every Tongkat buyer should ask first: does my body respond to this molecule at all? Generic 200:1 extract from a manufacturer that publishes COAs, at $28/month, in a 60-day bottle. The trial-extract chemistry isn't here; the QC and the price-to-discovery ratio is. This bottle should not be your destination. If you respond, upgrade to LJ100 (Double Wood #2) for cycle two — same brand, same QC, the patented extract behind Talbott 2013. If you've already cycled a generic and want max potency, Toniiq UHP (#1) is where the spend stops paying for marketing and starts paying for active mg. This bottle's job is to be the cheapest 'is Tongkat worth investigating' filter for the 30-40% of buyers who won't respond regardless of extract. The budget math: $28/month × 2 months = $56 to find out if Tongkat is a real lever for your physiology. The same $56 buys you 6 weeks of Toniiq — half the timeline for the discovery question, and at twice the price per discovery. For someone who's never run Tongkat, Double Wood 200:1 is the cleaner spend. Buy it, run it 8 weeks, decide on cycle two from data.
Check Double Wood Supplements · 200:1 root extract · 1000 mg cap on AmazonSame brand, patented LJ100 extract behind the Talbott 2013 trial — $10/month more for trial-validated material. The honest upgrade path after this bottle.
See it on the list →Cycle-two maxxer pick. Highest per-cap active eurycomanone on the consumer market, $45/month. Earn the upgrade by responding here first.
See it on the list →If $28 still hurts, Nutricost is the deeper budget pick at $15/month. Lower QC, no batch COA — but a workable budget filter if Double Wood is out of range.
See it on the list →200 mg/day standardised Tongkat for 4 weeks reduced cortisol 16% and raised T 37% vs placebo. The generic-extract bottle inherits the directional effect indirectly — same molecule, less-characterised material.
200 mg/day for 1 month raised total + free T above lower-normal in 90% of late-onset hypogonadism subjects. Frames the trial-window dose this 1000 mg generic cap is meant to approximate.
400 mg/day standardised Tongkat for 5 weeks improved muscle strength and free T in active seniors. Establishes the strength-outcome literature backing all Tongkat extracts.
400 mg/day standardised Tongkat for 24 weeks improved body composition vs placebo. Six-month safety data — supports the 8-week cycle this bottle is engineered for.
Pooled five-RCT meta-analysis: standardised mean difference of 1.35 on total T vs placebo across 100-600 mg/day. The size of the published Tongkat effect this generic 200:1 inherits, blurred by batch-to-batch variance.
One free quiz · personalized AI Coach path · 4 missions this week. Build your character, build your life.
